Analysts Set Cryoport, Inc. (NASDAQ:CYRX) PT at $11.00

Cryoport, Inc. (NASDAQ:CYRX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the seven ratings firms that are currently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $11.00.

Several analysts recently issued reports on CYRX shares. Roth Mkm reissued a "buy" rating and issued a $15.00 price target on shares of Cryoport in a research report on Tuesday, April 1st. Morgan Stanley dropped their price objective on Cryoport from $8.00 to $7.00 and set an "equal weight" rating on the stock in a research note on Monday, May 5th. Guggenheim reiterated a "buy" rating and set a $10.00 target price on shares of Cryoport in a research note on Wednesday, April 16th. UBS Group lifted their price objective on Cryoport from $10.00 to $11.00 and gave the stock a "buy" rating in a report on Tuesday, April 1st. Finally, Needham & Company LLC reissued a "buy" rating and issued a $11.00 price objective on shares of Cryoport in a report on Thursday, May 8th.

Insider Buying and Selling

In related news, Director Robert J. Hariri sold 12,500 shares of the business's stock in a transaction that occurred on Wednesday, May 28th. The stock was sold at an average price of $6.10, for a total value of $76,250.00. Following the completion of the sale, the director now owns 8,061 shares in the company, valued at $49,172.10. The trade was a 60.79% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Jerrell Shelton sold 4,620 shares of the business's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $6.29, for a total value of $29,059.80. Following the completion of the sale, the chief executive officer now owns 765,399 shares of the company's stock, valued at $4,814,359.71. The trade was a 0.60% decrease in their position. The disclosure for this sale can be found here. Insiders sold 32,330 shares of company stock worth $194,603 in the last quarter. 10.10% of the stock is owned by insiders.

Institutional Trading of Cryoport

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Cadian Capital Management LP increased its stake in shares of Cryoport by 14.1% during the fourth quarter. Cadian Capital Management LP now owns 4,927,027 shares of the company's stock valued at $38,332,000 after buying an additional 609,021 shares during the period. Millennium Management LLC grew its stake in shares of Cryoport by 11.0% in the fourth quarter. Millennium Management LLC now owns 4,139,869 shares of the company's stock worth $32,208,000 after acquiring an additional 409,353 shares during the last quarter. Deutsche Bank AG boosted its position in shares of Cryoport by 0.9% during the fourth quarter. Deutsche Bank AG now owns 1,397,121 shares of the company's stock valued at $10,870,000 after buying an additional 12,864 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Cryoport by 8.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 850,216 shares of the company's stock valued at $6,615,000 after buying an additional 63,301 shares during the last quarter. Finally, Silvercrest Asset Management Group LLC boosted its position in shares of Cryoport by 77.0% during the fourth quarter. Silvercrest Asset Management Group LLC now owns 742,914 shares of the company's stock valued at $5,780,000 after buying an additional 323,216 shares during the last quarter. Institutional investors own 92.90% of the company's stock.

Cryoport Stock Performance

Shares of NASDAQ:CYRX traded up $0.11 on Tuesday, hitting $6.06. The company had a trading volume of 338,127 shares, compared to its average volume of 541,818. Cryoport has a 1-year low of $4.58 and a 1-year high of $11.64. The stock has a market cap of $303.83 million, a price-to-earnings ratio of -1.79 and a beta of 1.92. The stock has a 50 day moving average price of $5.92 and a 200 day moving average price of $6.75. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48.

Cryoport (NASDAQ:CYRX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.01. The business had revenue of $41.04 million during the quarter, compared to analysts' expectations of $56.19 million. Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. Analysts expect that Cryoport will post -0.99 EPS for the current year.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.